Mounjaro®
Starting from £179.99/mo
Start journey Learn moreLower back pain during Wegovy treatment is something a meaningful number of people notice, and it is worth understanding what is actually going on. Semaglutide does not directly target spinal tissue, but the changes it sets in motion — gastrointestinal, musculoskeletal, even kidney-related — can each produce back discomfort through different routes. Whether the pain is listed in the official prescribing information, linked to rapid weight change, or a sign that something needs urgent attention, the mechanisms are distinct and worth separating clearly. These are prescription-only medicines, and any new or persistent back pain during treatment should be discussed with a clinician who knows your history.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
The first practical task is telling the different patterns apart, because they have very different implications. There are broadly three routes by which Wegovy treatment intersects with lower back discomfort, and a fourth scenario that sits outside that category entirely because it requires urgent action.
Mild, diffuse aching in the lower back that comes and goes is the most common pattern. It tends to appear in the early weeks of treatment alongside the better-known gastrointestinal effects (nausea, constipation, bloating) and often settles as the body adjusts. The NHS medicines page for semaglutide lists back pain among the reported side effects, though it is not among the most frequent ones. This type of pain is generally mild, does not worsen steadily, and is not accompanied by other alarming symptoms.
Musculoskeletal aching tied to postural shift is a second pattern, most noticeable when weight is falling relatively quickly. The spine and the muscles around it have adapted over years to carrying a certain load and holding a particular centre of gravity. As that changes, the adjustment is not always smooth. Some people describe a low-level ache in the lumbar region, especially after standing or walking for longer than usual, that was not there before treatment started. Our detailed guide to back pain and Wegovy covers why this pattern occurs and what typically helps. This is not unique to Wegovy (it is a known feature of significant weight loss by any route) but it can feel confusing if the connection is not obvious.
Referred pain from gut activity is the third pattern. When the bowel is sluggish (a side effect constipation can produce) pressure can translate into discomfort felt as lower back pain rather than abdominal pain. Similarly, gas and bloating can radiate posteriorly. People are often surprised that what feels like a back problem is actually digestive in origin, and our page looking at whether Wegovy can cause back pain explains the different mechanisms behind this in more detail. Increasing fluid intake and, where your prescriber recommends it, dietary fibre often reduces this type of discomfort significantly.
There is one presentation of back pain that has nothing to do with posture or gut motility and must not be managed at home: severe, persistent stomach pain that builds over hours and radiates through to the back, particularly in the middle or upper back, sometimes accompanied by vomiting or fever.
This pattern is a classic presentation of acute pancreatitis. In January 2026 the MHRA issued a Drug Safety Update specifically flagging acute pancreatitis as a known, infrequently occurring but potentially serious side effect of GLP-1 medicines including semaglutide. You can report suspected side effects and seek guidance via the Yellow Card scheme, but pancreatitis is not a Yellow Card situation to handle calmly at home, it is a 999 or A&E situation. Stop treatment and get medical help the same day if pain is severe, spreading and not easing.
It is also worth being aware that kidney function can be affected by severe dehydration from vomiting or diarrhoea, and kidney-related pain can present in the flank and lower back. Again, if gastrointestinal symptoms have been severe and back pain follows, tell a clinician rather than waiting it out.
If you are uncertain which pattern you are experiencing, the right move is always to contact your prescriber. A question our clinical team hears regularly is whether a symptom is serious enough to warrant attention, the answer is nearly always: if you are wondering, it is worth checking.
For the mild, transient back pain that sits in the first or third pattern above, a few straightforward things tend to help. Staying well hydrated matters more on Wegovy than usual, because dehydration worsens both the GI side effects and the secondary back discomfort they can produce. Moving regularly (short walks, gentle stretching) is preferable to prolonged sitting, which increases lumbar load regardless of treatment status.
If you are injecting Wegovy into the back of the upper arm, rotate your injection site properly to avoid localised tissue discomfort that can occasionally spread. Do not change your dose schedule, skip doses or stop treatment because of mild back pain without speaking to your prescriber first, the Patient Information Leaflet and your prescribing pharmacist or doctor are the right resources for any dose-related decisions.
If back pain is persistent beyond two or three weeks, or is getting worse rather than better, that warrants a clinical conversation. It may be unrelated to Wegovy entirely, pre-existing musculoskeletal conditions do not pause because a new treatment has started. A prescriber familiar with how semaglutide works can help distinguish between treatment-related and coincidental causes, and advise whether continuing, pausing or adjusting is appropriate in your specific case. It is also worth knowing that Wegovy can lower blood sugar, which is relevant context if you have diabetes or any metabolic condition your prescriber is monitoring alongside your back symptoms.
Some readers arrive at this page after stopping treatment and finding back pain persists, or after restarting Wegovy and noticing the pain returns. That pattern of re-emergence with dosing is clinically meaningful and worth reporting to your prescriber in detail. There is more on what happens to weight and symptoms if treatment is stopped on our page about weight returning after Wegovy.
If you are already on Wegovy and concerned, contact whoever prescribed your treatment. At nume, aftercare is available seven days a week, there is no waiting for a scheduled review slot if something feels wrong. Our clinical team reviews each concern personally. That matters when a symptom like back pain has several plausible explanations with very different appropriate responses.
If you are researching Wegovy before starting and lower back pain is a concern because of a pre-existing spinal condition, this is exactly the kind of thing that belongs in a consultation rather than a general article. The prescriber assesses your full medical history, including musculoskeletal conditions, before any treatment is approved. Wegovy is a prescription-only medicine and requires that individual clinical review regardless of which pharmacy or service you use. You can read more about what the weight-loss treatment options available in the UK actually involve before deciding whether to proceed.
For those ready to explore whether Wegovy is appropriate for them, check your eligibility with a free consultation. A GPhC-registered prescriber reads every application personally, the same day.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.